lipidoid | 1609534-47-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: lipidoid
• 英文别名: 1-[3-[2-Hydroxyhexadecyl(methyl)amino]propyl-methylamino]hexadecan-2-ol
• CAS: 1609534-47-5
• 化学式: C₃₇H₇₈N₂O₂
• 分子量: 583.039
• InChiKey: NERXWMXSKBHHTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  13.8
• 重原子数：
  41
• 可旋转键数：
  34
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1,2-环氧十六烷 、 N,N'-二甲基-1,3-丙二胺 以 neat (no solvent) 为溶剂， 反应 48.0h， 生成 lipidoid
  参考文献：
  名称：

  组合设计的脂质样纳米颗粒用于细胞毒性蛋白的细胞内递送，用于癌症治疗

  摘要：

  对于推进基于蛋白质的治疗方法，非常需要一种有效，安全的方法来将活性蛋白递送到靶细胞的胞质溶胶中。通过阳离子脂质样材料（称为“脂质”）的组合设计，以及可逆的化学蛋白质工程方法，创建了一个新型的蛋白质递送平台。使用核糖核酸酶A（RNase A）和皂草素作为两种代表性的细胞毒性蛋白，组合类脂质有效地将蛋白传递到癌细胞中并抑制细胞增殖。对结构-功能关系的研究表明，类脂质与蛋白质之间的静电和疏水相互作用在蛋白质-类脂质纳米复合物的形成和细胞内传递中起着至关重要的作用。

  DOI：

  10.1002/anie.201311245

文献信息

• NANOCOMPLEXES OF MODIFIED PEPTIDES OR PROTEINS
  申请人：Tufts University

  公开号：US20160129120A1

  公开（公告）日：2016-05-12

  A nanocomplex containing a delivery agent and a pharmaceutical agent. The nanocomplex has a particle size of 50 to 1000 nm, the delivery agent binds to the pharmaceutical agent via non-covalent interaction or covalent bonding, and the pharmaceutical agent is a modified peptide or protein formed of a peptide or protein and an added chemical moiety that contains an anionic group, a disulfide group, a hydrophobic group, a pH responsive group, a light responsive group, a reactive oxygen species responsive group, or a combination thereof.

  一种纳米复合物，包含传递剂和药物剂。该纳米复合物的粒径为50至1000纳米，传递剂通过非共价作用或共价键合与药物剂结合，药物剂是一种修饰的肽或蛋白质，由肽或蛋白质和含有负离子基团、二硫键基团、疏水基团、pH响应基团、光响应基团、反应性氧化物种响应基团或其组合的添加化学基团组成。
• [EN] NOVEL NUCLEIC ACID MODIFIERS<br/>[FR] NOUVEAUX MODIFICATEURS D'ACIDE NUCLÉIQUE
  申请人：BROAD INST INC

  公开号：WO2019135816A9

  公开（公告）日：2019-10-17
• LIPIDIC COMPOUND-TELODENDRIMER HYBRID NANOPARTICLES AND METHODS OF MAKING AND USES THEREOF
  申请人：The Research Foundation for The State University of New York

  公开号：US20170266292A1

  公开（公告）日：2017-09-21

  Lipidic compound (lipidic molecule)-telodendrimer hybrid nanoparticles. For example, the lipidic compound-telodendrimer hybrid nanoparticles are lipid/lipidoid-telodendrimer hybrid nanoparticles. The nanoparticles can comprise a plurality of lipidic molecules (e.g., lipid molecules, lipidoid molecules, or mixtures of different lipid molecules or different lipidoid molecules). The hybrid nanoparticles can comprise one or more lipid or lipidoid and one or more telodendrimer. The hybrid nanoparticles can also comprise cholesterol. In various examples, the hybrid nanoparticles also comprise a small molecule, peptide, protein, or a combination thereof. In various examples, lipid-telodendrimer hybrid nanoparticles comprising one or more small molecules or lipidoid-telodendrimer hybrid nanoparticles comprising one or more protein(s) and/or peptide(s) are used in methods of small-molecule or protein/peptide delivery.
• [EN] NOVEL CRISPR ENZYMES AND SYSTEMS<br/>[FR] NOUVEAUX SYSTÈMES ET ENZYMES CRISPR
  申请人：BROAD INST INC

  公开号：WO2018035387A1

  公开（公告）日：2018-02-22

  In one aspect, embodiments disclosed herein are directed to engineered CRISPR-Cas effector proteins that comprise at least one modification compared to an unmodified CRISPR-Cas effector protein that enhances binding of the of the CRISPR complex to the binding site and/or alters editing preference as compared to wild type. In certain example embodiments, the CRISPR-Cas effector proteins a Type II effector protein. In certain other example embodiments, the Type V effector protein is Cas9 or an orthologs or engineered variant thereof. Example Cas9 proteins suitable for use in the embodiments disclosed herein are discussed in further detail below.
• [EN] TYPE VII CRISPR PROTEINS AND SYSTEMS<br/>[FR] SYSTÈMES ET PROTÉINES CRISPR DE TYPE VII
  申请人：BROAD INST INC

  公开号：WO2020191102A1

  公开（公告）日：2020-09-24

  The present application provides systems, methods and compositions used for targeted gene modification, targeted insertion, perturbation of gene transcripts, and nucleic acid editing. Novel nucleic acid targeting systems comprise components of Type VII Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems and transposable elements.